Your browser doesn't support javascript.
loading
The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine.
Aarnoutse, Romy; Ziemons, Janine; de Vos-Geelen, Judith; Valkenburg-van Iersel, Liselot; Wildeboer, Aurelia C L; Vievermans, Anne; Creemers, Geert-Jan M; Baars, Arnold; Vestjens, Hanneke J H M J; Le, Giang N; Barnett, David J M; Rensen, Sander S; Penders, John; Smidt, Marjolein L.
Afiliación
  • Aarnoutse R; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Ziemons J; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • de Vos-Geelen J; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Valkenburg-van Iersel L; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Wildeboer ACL; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Vievermans A; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Creemers GM; Department of Medical Oncology, Catharina Hospital, Eindhoven, The Netherlands.
  • Baars A; Department of Medical Oncology, Hospital Gelderse Vallei, Ede, The Netherlands.
  • Vestjens HJHMJ; Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands.
  • Le GN; Department of Medical Microbiology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Barnett DJM; Department of Medical Microbiology, Maastricht University Medical Centre, Maastricht, The Netherlands; Maastricht Centre for Systems Biology (MaCSBio), Maastricht University, Maastricht, The Netherlands.
  • Rensen SS; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands; NUTRIM - School of Nutrition and Translational research In Metabolism, Maastricht University, Maastricht, The Netherlands.
  • Penders J; Department of Medical Microbiology, Maastricht University Medical Centre, Maastricht, The Netherlands; NUTRIM - School of Nutrition and Translational research In Metabolism, Maastricht University, Maastricht, The Netherlands.
  • Smidt ML; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. Electronic address: m.smidt@mumc.nl.
Clin Colorectal Cancer ; 21(2): e87-e97, 2022 06.
Article en En | MEDLINE | ID: mdl-34801414
ABSTRACT

BACKGROUND:

Previous pre-clinical research has indicated that the intestinal microbiota can potentiate anti-tumour efficacy of capecitabine and that capecitabine treatment impacts intestinal microbiota composition and diversity. Using a longitudinal design, this study explores the associations between the intestinal microbiota and treatment response in patients with metastatic colorectal cancer (mCRC) during capecitabine treatment. PATIENTS AND

METHODS:

Patients with mCRC treated with capecitabine were prospectively enrolled in a multicentre cohort study. Patients collected a faecal sample and completed a questionnaire before, during, and after three cycles of capecitabine. Several clinical characteristics, including tumour response, toxicity and antibiotic use were recorded. Intestinal microbiota were analysed by amplicon sequencing of the 16S rRNA V4 gene-region.

RESULTS:

Thirty-three patients were included. After three cycles of capecitabine, six patients (18%) achieved a partial response, 25 (76%) showed stable disease, and one (3%) experienced progressive disease. Of the 90 faecal samples were collected. Microbial diversity (α-diversity), community structure (ß-diversity), and bacterial abundance on phylum and genus level were not significantly different between responders and non-responders and were not significantly affected by three cycles of capecitabine.

CONCLUSION:

This is the first clinical study with longitudinal intestinal microbiota sampling in mCRC patients that explores the role of the intestinal microbiota during treatment with capecitabine. Intestinal microbiota composition and diversity before, during, and after three cycles of capecitabine were not associated with response in this study population. Capecitabine did not induce significant changes in the microbiota composition and diversity during the treatment period. Individual effects of antibiotics during capecitabine treatment were observed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Colorrectales / Microbioma Gastrointestinal Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Colorectal Cancer Asunto de la revista: GASTROENTEROLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Colorrectales / Microbioma Gastrointestinal Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Colorectal Cancer Asunto de la revista: GASTROENTEROLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos